| Subject: | FDA Issues Warning On Inappropriate Use of Bicillin C-R |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Thu, 2 Dec 2004 - 10:00 am |
| The FDA and King Pharmaceuticals, Inc., have issued a reminder to healthcare professionals regarding the use of Bicillin C-R. Bicillin C-R is a mixture of 1.2 million units of benzathine penicillin G (BPG) and 1.2 mission units of procaine penicillin G. Bicillin C-R is intended for the treatment of moderately severe infections due to penicillin G susceptible microorganisms, such as upper respiratory infections, scarlet fever, skin and soft-tissue infections due to susceptible streptococci. The... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
Customizable Documents and Tools:
Related MCN Products:
|
|
StayAlert!® Virtual Compliance Administrator™ keeps clients informed by email of any changes to Federal regulations, including Joint Commission (TJC, formerly JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG, and many more, and also provides downloadable tools to ensure compliance. StayAlert! is a premium product sold as an annual site-license subscription. With the site license, the client can sign up an unlimited number of users for the email alerts and access to the StayAlert! online regulatory library. The strength of StayAlert! rests in its ability to allow healthcare organizations to streamline their businesses using the Internet as a foundation architecture. StayAlert! provides cost containment and reduction through elimination of unnecessary overhead, and work caused by errors or poor access to information. |
|
